CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner
Qian‐Feng Zhang, Jia Li, Kuo Jiang, Rui Wang, Junli Ge, Hong Yang, Shujuan Liu, Lintao Jia, Lei Wang, Biliang Chen
Abstract
These findings suggest that combined treatment with CDK4/6i and anti-PD-1 antibody could improve the efficacy of anti-PD-1 therapy and hold great promise for the treatment of poorly immune-infiltrated ovarian cancer.
Topics & Concepts
BlockadeCancer researchImmune systemOvarian cancerInfiltration (HVAC)ChemistryPD-L1Immune checkpointCell biologyPharmacologyBiologyMedicineCancerImmunologyReceptorImmunotherapyInternal medicineMaterials scienceBiochemistryComposite materialAdvanced Breast Cancer TherapiesCancer Immunotherapy and BiomarkersCancer Mechanisms and Therapy